Nirogacestat treatment for Kaposi sarcoma
Treatments studied
Part of Cancer, Infections, Skin clinical trials.
This study tests a new drug called nirogacestat to treat Kaposi sarcoma (a cancer that causes abnormal tissue growth, usually on the skin). The drug works by blocking a protein that helps cancer cells grow. You may qualify if you have biopsy-confirmed Kaposi sarcoma on your skin, haven't responded to previous treatments, or are newly diagnosed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Biopsy-proven Kaposi sarcoma on the skin (newly diagnosed, or hasn't improved with prior treatments)
- Enough accessible skin lesions for biopsies: either six lesions at least 4 mm in size, or one larger lesion 20 mm that can be repeatedly biopsied, plus at least five more measurable lesions with no improvement in the past month
- Blood counts and organ function within safe ranges (checked within 3 months): hemoglobin at least 8, white blood cells at least 1,000, platelets at least 100,000, kidney function adequate, liver function acceptable
- If HIV-positive: stable antiretroviral therapy for at least 12 weeks, with CD4 count above 50 and viral load below 200 copies
- Age 18 or older, good enough health to handle the treatment (life expectancy at least 3 months), and able to follow the study requirements including strict contraception for 7 days after treatment ends
- Willingness to provide multiple biopsies and commit to pregnancy prevention if of childbearing potential
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests paclitaxel plus pegylated liposomal doxorubicin (two IV chemotherapy medicines) for HIV-related Kaposi sarcoma (KS). It may help shrink KS lesions and improve quality of life in people with certain stages of KS and enough heart, blood, and liver function to safely receive treatment.
This trial tests if the blood pressure medication propranolol can treat Kaposi Sarcoma (a type of skin cancer) in adults. You may be able to join if you have at least 7 measurable skin lesions and are otherwise healthy enough to take an oral pill.
This trial tests a special imaging device to see if it can better evaluate Kaposi sarcoma skin lesions. It may help doctors understand the extent of the disease without relying only on physical exams.
This trial tests an experimental drug (CYT107) that boosts the immune system to help fight Kaposi sarcoma in people with HIV who have a low CD4 count despite good HIV treatment. It aims to see if the drug can improve KS tumors and quality of life.
This trial studies ixazomib (a targeted anti-cancer medicine) to treat cutaneous (skin) Kaposi sarcoma. It aims to shrink measurable skin lesions and improve symptoms, especially in people living with HIV.
This Phase 1/2 study tests PDS01ADC, a targeted cancer drug, for advanced Kaposi sarcoma (KS). It also studies how well the drug works when added to the immunotherapy M7824, especially if KS has not responded to prior treatments.
Hear when a new AIDS-Related Kaposi Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.